CompletedEUCTR 2008-001767-11
A Randomized, Controlled, Open-Label Comparison Study of the Efficacy and Safety of Slow Transitioning compared with Fast Transitioning from a Stimulant Medication to Atomoxetine in Pediatric and A...
This historical record does not confirm current site availability.
Historical research recordMultiple countriesADHD
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Portugal · Spain and 1 more location
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 120
- Sponsor
- Eli Lilly and Company Limited
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United Kingdom, Portugal, Spain
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2008-001767-11
- Official title
Show the full official title
A Randomized, Controlled, Open-Label Comparison Study of the Efficacy and Safety of Slow Transitioning compared with Fast Transitioning from a Stimulant Medication to Atomoxetine in Pediatric and A...
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Portugal · Spain · United Kingdom
Registry details
Historical country statuses
- Spain — Completed
- United Kingdom — Completed
- Portugal — Completed
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company Limited.
Want to explore more studies?
Explore studiesRelated studies
Atomoxetine or placebo to maintain response in adult ADHD
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS® methylphenidate (54 and 72 mg/day) i...